Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose of a treatment that utilizes four widely available malaria drugs, according ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...
Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with ...
Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune ...
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...
News Medical on MSN
New combination treatment overcomes resistance in ER positive breast cancer
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School ...
Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved in focal ...
More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback